• Patients receiving VP-001 demonstrate sustained improvement in vision in the treated eye up to 18 months
• VP-001 treated eye outperforms both the 'fellow' (untreated) eye and natural history control group
• VP-001 continues to demonstrate a favourable safety/tolerability profile with no serious adverse events

PYC Therapeutics is developing an investigational drug candidate (VP-001) to treat the blinding eye disease Retinitis Pigmentosa type 11 (RP11). The company today announces that patients receiving VP-001 as part of the ongoing Phase 1/2 clinical trials have sustained improvements in both functional vision and retinal sensitivity through 18 months of follow-up. The VP-001 treated eye outperforms both the 'fellow' (untreated) eye in patients as well as the natural history control group across all registrational endpoints measured, including low luminance visual acuity and microperimetry. VP-001 continues to demonstrate a favourable safety/tolerability profile with no treatment-related serious adverse events reported in any patient dosed with the drug candidate to date. PYC is preparing to engage the US Food and Drug Administration (FDA) to align on a registrational trial design ahead of expected commencement of this study in 2026.

PYC is in the final stages of preparing for a Type D meeting with the US FDA to align on a registrational trial pathway in RP11. The Company expects to initiate the registrational trial in 2026 following completion of the Type D meeting in Q1 2026.